Stabilizing cancer-fighting p53 can also shield a metastasis-promoter

May 22, 2008

Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the protein, causing cancer cells to thrive and spread rather than die, according to research by scientists at The University of Texas M. D. Anderson Cancer Center reported in the current issue of the journal Genes and Development.

"As we develop therapies to restore the function of p53, we need to make sure we first know what version of this gene is present in a patient's tumor and then decide how to treat it," said senior author Guillermina Lozano, Ph.D., professor and chair of M. D. Anderson's Department of Cancer Genetics.

The research shows that attempting to restore normal expression of p53 protein by blocking another protein that normally degrades p53 can have the perverse effect of protecting mutated p53 and promoting metastasis.

The p53 gene is inactivated in many types of cancer. Its normal role is to halt the division of a defective cell and then force the cell to kill itself or deprive the cell of its ability to reproduce. As such, reactivation of p53 is thought to have great therapeutic potential.

Normally, p53 levels are low, but it springs into action in response to DNA damage or activation of cancer-promoting genes, or oncogenes.

Lozano, an expert on mouse models of human cancer, and colleagues developed mice with a specific mutation of p53 that mimics a common genetic mutation in human cancers. The mutated gene, called p53H, expresses a defective version of the p53 protein.

When mice had the p53H mutation on both genes (p53 H/H), the researchers found that the p53 protein was not detectable in normal tissue but was present in 79 percent of tumors. However, tumors in these mice did not metastasize.

Enter Mdm2, a protein whose normal job is to degrade p53 when it's no longer needed. Mdm2 also degrades the mutated version of the p53 protein.

The researchers developed p53 mutant mice that lacked one or both copies of Mdm2. Mice with the double-mutant p53 that also had no Mdm2 died sooner and developed more aggressive metastatic tumors than mice with only the p53 mutation.

The frequency of metastasis went from zero in the p53 H/H with normal Mdm2, to 9 percent in mice lacking one copy of Mdm2 to 17 percent in mice with no Mdm2. Metastasis - the invasive spread of cancer to other organs - causes 90 percent of all human cancer deaths.

Absence of a second tumor-suppressing gene, p16, also promotes stability of mutant p53.

"The importance of this study cannot be overemphasized," the researchers concluded. Drugs that try to protect normal p53 by inhibiting the p53-degrading protein Mdm2 also would protect mutant p53 "with dire consequences."

By the same token, chemotherapy that seeks to stabilize p53 could also stabilize the mutant version. Detecting the type of p53 present in a tumor is possible with current lab technology, Lozano said.

The study raises the possibility of suppressing cancer metastasis by eliminating mutant p53 stability, which the researchers note is more feasible than converting mutant p53 to the normal type.

Source: University of Texas M. D. Anderson Cancer Center

Explore further: New function of obesity gene revealed

Related Stories

New material set to change cooling industry

13 hours ago

Refrigeration and air conditioning may become more efficient and environmentally friendly thanks to the patent-pending work of LSU physicists. The team of researchers led by LSU Physics Professor Shane Stadler ...

Hair today, communication trigger tomorrow

14 hours ago

Beauty technology? Don't be concerned if at first you missed the mark. "Beauty technology" does not refer to how ingredients are processed and packaged on shampoo and soap assembly lines. Katia Vega is a ...

Mass beaching fuels 'unscientific' Japan quake fears

14 hours ago

The mass beaching of more than 150 melon-headed whales on Japan's shores has fuelled fears of a repeat of a seemingly unrelated event in the country—the devastating 2011 undersea earthquake that killed ...

Recommended for you

New function of obesity gene revealed

19 hours ago

Scientists have discovered a previously unknown mechanism behind how the fat mass and obesity associated (FTO) gene promotes obesity. Their findings may have important implications for future therapeutic ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

gdpawel
not rated yet Jun 11, 2008
Dealing With Targeted Resistance

This study is on the same plane as another recent study by researchers at M.D. Anderson. They have found that EGFR drugs home in on a receptor that is abundant on the surface of cancer cells. But it turns out that the receptor, despite interference from the drugs, also helps the cancer cells thrive by helping to assure their food supply.

Drugs like Erbitux, Avastin, Tarceva, Iressa, and Vectibix by blocking this receptor disrupts cellular signals that cause signals that cause tumor cells to grow and proliferate. They work by preventing the enzyme tyrosine kinase from launching a signaling cascade that fuels tumor cell growth.

But generally limited responses of 10% to 20% to these treatments have casued cancer experts to wonder if EGFR's role in the disease is limited as well. EGFR could play a second role in promoting the survival of cancer cells. It helps tumor cells get a constant and plentiful supply of the sugar glucose, a critical nutrient.

EGFR does this by binding to and stabilizing another protein on the cell surface called SGLT1 (sodium/glucose co-transporter). Without this mechanism, the cell will undergo glucose starvation. The cell essentially devours itself and dies.

The glucose role is independent and thus unaffected by turning off the kinase-activated growth signals. The tumor cell that expresses very high levels of EGFR and very high levels of SGLT will remain viable.

That is why most any targeted drugs are poorly-predicted by measuring a preferred target or two. They can be well-predicted by measuring the effect of the drugs on the function of live cells. There are many pathways/mechanisms to altered cellular function, hence all the different pathays/mechanisms which correlate in different situations.

Improvement can be made by measuring what happens at the end of all processes, rather than the status of the individual pathways/mechanisms. You still need to measure the net effect of all processes, not just the individual molecular targets.

Many of these drugs cry out for validated clinical biomarkers as pharmacodynamic endpoints and with the ability to measure multiple parameters in cellular screens now in hand using flow cytometry to help set dosage and select people likely to respond.

The importance of mechanistic work around targets as a starting point for drug development should be downplayed in favor of a systems biology (cell function analysis) approach were compounds are first screened in cell-based assays, with mechanistic understanding of the target coming only after validation of its impact on the biology.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.